DK1309860T3 - Fremgangsmåde til screening af peptider til anvendelse i immunterapi - Google Patents

Fremgangsmåde til screening af peptider til anvendelse i immunterapi

Info

Publication number
DK1309860T3
DK1309860T3 DK01956629T DK01956629T DK1309860T3 DK 1309860 T3 DK1309860 T3 DK 1309860T3 DK 01956629 T DK01956629 T DK 01956629T DK 01956629 T DK01956629 T DK 01956629T DK 1309860 T3 DK1309860 T3 DK 1309860T3
Authority
DK
Denmark
Prior art keywords
iia
class
identifying
peptide
subdominant
Prior art date
Application number
DK01956629T
Other languages
English (en)
Inventor
Kostas Kosmatopoulos
Sophie Tourdot
Antonio Scardino
David Alexandre Gross
Original Assignee
Inst Nat Sante Rech Med
Inst Gustave Roussy Igr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Inst Gustave Roussy Igr filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1309860T3 publication Critical patent/DK1309860T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
DK01956629T 2000-07-21 2001-07-20 Fremgangsmåde til screening af peptider til anvendelse i immunterapi DK1309860T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0009591A FR2812087B1 (fr) 2000-07-21 2000-07-21 Procede de criblage de peptides utilisables en immunotherapie
PCT/FR2001/002387 WO2002008716A2 (fr) 2000-07-21 2001-07-20 Procede de criblage de peptides utilisables en immunotherapie

Publications (1)

Publication Number Publication Date
DK1309860T3 true DK1309860T3 (da) 2008-03-17

Family

ID=8852782

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01956629T DK1309860T3 (da) 2000-07-21 2001-07-20 Fremgangsmåde til screening af peptider til anvendelse i immunterapi

Country Status (11)

Country Link
US (2) US7425606B2 (da)
EP (1) EP1309860B1 (da)
AT (1) ATE378590T1 (da)
AU (1) AU2001278555A1 (da)
CA (1) CA2416761C (da)
DE (1) DE60131413T2 (da)
DK (1) DK1309860T3 (da)
ES (1) ES2296778T3 (da)
FR (1) FR2812087B1 (da)
PT (1) PT1309860E (da)
WO (1) WO2002008716A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
MXPA02007478A (es) 2000-02-04 2004-08-23 Univ Duke Vacuna contra el virus de inmunodeficiencia humana.
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
DE602006006046D1 (de) 2005-05-09 2009-05-14 Vaxon Biotech Verwendung nativer peptide und deren optimierter derivate zur impfung
ATE435660T1 (de) * 2005-12-23 2009-07-15 Vaxon Biotech Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
AU2012258603A1 (en) 2011-05-26 2014-01-16 Geneius Biotechnology, Inc. Modulated immunodominance therapy
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1995027901A1 (en) * 1994-04-11 1995-10-19 Ixsys, Inc. Class i peptide binding motifs
ES2314515T3 (es) * 1996-03-21 2009-03-16 Circassia Limited Peptidos cripticos y metodo para su identificacion.
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
AU1331100A (en) * 1998-10-29 2000-05-22 Dana-Farber Cancer Institute Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Also Published As

Publication number Publication date
WO2002008716A3 (fr) 2003-02-27
US7976843B2 (en) 2011-07-12
EP1309860A2 (fr) 2003-05-14
AU2001278555A1 (en) 2002-02-05
US7425606B2 (en) 2008-09-16
US20090269363A1 (en) 2009-10-29
DE60131413T2 (de) 2008-09-04
CA2416761C (fr) 2013-04-23
PT1309860E (pt) 2008-02-25
ATE378590T1 (de) 2007-11-15
FR2812087A1 (fr) 2002-01-25
CA2416761A1 (fr) 2002-01-31
DE60131413D1 (de) 2007-12-27
WO2002008716A2 (fr) 2002-01-31
ES2296778T3 (es) 2008-05-01
US20040072240A1 (en) 2004-04-15
EP1309860B1 (fr) 2007-11-14
FR2812087B1 (fr) 2007-05-11

Similar Documents

Publication Publication Date Title
DK1309860T3 (da) Fremgangsmåde til screening af peptider til anvendelse i immunterapi
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
Touloukian et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
JP2905170B2 (ja) オリゴマー化ペプチド−ｍｈｃ分子複合体
WO2006076410A3 (en) Li-key/antigenic epitope hybrid peptide vaccines
NO990533L (no) GnRH-leukotoksin kimµrer
BR9406652A (pt) Composição
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
DK1218751T3 (da) Cöliakidiagnose under anvendelse af et gliadinepitop
DK1002110T3 (da) Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
BR9813416A (pt) Composições e métodos de nodavìrus recombinante
BRPI0508551A (pt) seqüências de ácidos nucléicos de lactobacillus acidophilus que codificam proteìnas relacionadas à utilização de carboidrato e usos dessas
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
NO995002D0 (no) Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA
WO2006066229A3 (en) Elicitation of antibodies to self peptides by immunization with dendritic cells
CA2542104A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
DK0880360T3 (da) Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
EP2649091A1 (en) Immune restricted peptides with increased efficacy
Krikorian et al. A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates
AP2368A (en) Novel expression vectors and uses thereof.
Posthuma et al. Proteosomal degradation of BCR/ABL protein can generate an HLA-A* 0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated
Stewart et al. Protein NH2-terminal asparagine deamidase. Isolation and characterization of a new enzyme.
CA2819978A1 (en) Immune restricted peptides with increased efficacy
Rhodes et al. Isolation and characterization of the cyanogen bromide peptides derived from the human. alpha. 2 (V) collagen chain